@article{page_thrall_george_price_heidner_mcentee_novotney_hauck_dewhirst_1992, title={QUANTITATIVE ESTIMATION OF THE THERMAL DOSE-MODIFYING FACTOR FOR CIS-DIAMMINEDICHLOROPLATINUM (CDDP) IN TUMOR-BEARING DOGS}, volume={8}, ISSN={["0265-6736"]}, DOI={10.3109/02656739209005024}, abstractNote={A statistical method for estimating clinical toxicity was used to determine a theoretical isoeffect dose-modifying factor for dogs with disseminated or refractory neoplasia treated with cis-diammine dichloroplatinum (II) plus whole-body hyperthermia or CDDP alone. CDDP was administered every 3 weeks with vigorous saline hydration to 54 dogs (CDDP alone n = 21, CDDP/WBH n = 33) that were eligible for entry into this non-randomized study. CDDP was administered during the plateau phase of WBH in dogs receiving combined therapy. Acute toxicity included myelosuppression (CDDP n = 7; CDDP/WBH n = 5), nephrotoxicity (CDDP n = 1, CDDP/WBH n = 1) and respiratory distress (CDDP/WBH n = 2). Eight dogs experienced chronic renal dysfunction as a result of CDDP (n = 2) or CDDP/WBH (n = 6). A theoretical thermal dose-modifying factor was determined for both acute and cumulative toxicity by comparing the maximum tolerated dose of each treatment group. The maximum tolerated dose (MTD) of CDDP +/- WBH was defined as that dose producing a 50% incidence of moderate acute toxicity or acute plus mild chronic toxicity as estimated from logistic regression analysis of the toxicity data. The MTD (+/- .standard error) of CDDP/WBH for acute toxicity only was 54.6 (4.3) mg/M2 and for CDDP alone the MTD was 73.6 (40) mg/M2. Thus, the isoeffect dose-modifying factor for acute toxicity was 1.35 (0.12). The MTD (SE) of CDDP/WBH for cumulative toxicity (acute plus chronic toxicity) was 46.4 (2.7) mg/M2 and for CDDP alone waas 70.0 (2.9) mg/M2. The isoeffect dose-modifying factor for total cumulative toxicity was 1.5 (0.1).(ABSTRACT TRUNCATED AT 250 WORDS)}, number={6}, journal={INTERNATIONAL JOURNAL OF HYPERTHERMIA}, author={PAGE, RL and THRALL, DE and GEORGE, SL and PRICE, GS and HEIDNER, GL and MCENTEE, MC and NOVOTNEY, CA and HAUCK, ML and DEWHIRST, MW}, year={1992}, pages={761–769} }
 @article{heidner_kornegay_page_dodge_thrall_1991, title={ANALYSIS OF SURVIVAL IN A RETROSPECTIVE STUDY OF 86 DOGS WITH BRAIN-TUMORS}, volume={5}, ISSN={["0891-6640"]}, DOI={10.1111/j.1939-1676.1991.tb00952.x}, abstractNote={A retrospective study of 86 dogs with brain tumors was undertaken. Sixty‐nine dogs had histologic confirmation of tumor type, whereas the remaining 17 dogs had CT evidence of a brain tumor. All dogs had neurologic abnormalities. Seven dogs received no treatment, 38 dogs received only symptomatic treatment, and 41 dogs received some form of definitive treatment, in addition to medical management. Types of definitive treatment included surgery, cobalt‐60 radiation, whole‐body hyperthermia, 125I implants, and chemotherapy, alone or in combination. The factor that was most associated with survival duration was mode of therapy. Those dogs who were treated with cobalt‐60 radiation, with or without other combinations of therapy, lived significantly longer than dogs who received surgery (±125I implants), or dogs who received symptomatic treatment (P= 0.01 and P < 0.001, respectively). After statistic adjustment for treatment, multiplicity of brain involvement (solitary vs. multiple) provided prognostic information with respect to survival (P= 0.001), with dogs who had a solitary site of involvement having a better prognosis. After further adjustment, initial neurologic dysfunction (mild/moderate vs. severe) showed significance as prognostic variable (P= 0.005). Both the mild and moderate groups had a more favorable prognosis compared with dogs who had severe initial neurologic impairment. The median survival time for the 86 dogs was 1.0 month (range: 1 day‐42.4 mo). Median survival times of dogs receiving: 1) no therapy or only symptomatic therapy, 2) surgery (±125I), or 3) cobalt‐60 radiation (± hyperthermia, ± surgery) were 0.2, 0.9, and 4.9 months, respectively.}, number={4}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={HEIDNER, GL and KORNEGAY, JN and PAGE, RL and DODGE, RK and THRALL, DE}, year={1991}, pages={219–226} }
 @article{heidner_page_mcentee_dodge_thrall_1991, title={TREATMENT OF CANINE APPENDICULAR OSTEOSARCOMA USING CO-60 RADIATION AND INTRAARTERIAL CISPLATIN}, volume={5}, ISSN={["0891-6640"]}, DOI={10.1111/j.1939-1676.1991.tb03143.x}, abstractNote={Twelve dogs with appendicular osteosarcoma were treated with 24–40 Gy of cobalt 60 radiation and two doses of intraarterial cisplatin. Improvement in limb function occurred in four dogs, and three dogs, which had only mild initial lameness, had no worsening of their lameness post‐treatment. In nine dogs in which local control was evaluable, eight had local failure, with the median (95% CI) duration of local control being 5.9 (4.6, 6.7) months. Two dogs had metastatic disease before therapy, and an additional nine dogs had metastatic disease at a median time of 6.4 months. Pathologic fracture was present in four dogs; two fractures occurred before treatment and two were documented at the time of tumor recurrence. Median (95% CI) survival time for all 12 dogs was 4.9 (3.4, 6.8) months. Excluding the two dogs with preexisting metastatic disease, median survival time was 6.7 months. Three dogs survived longer than 1 year. This mode of therapy was well tolerated and may be considered an alternative to amputation or limb‐sparing surgical procedures in selected dogs with appendicular osteosarcoma.}, number={6}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={HEIDNER, GL and PAGE, RL and MCENTEE, MC and DODGE, RK and THRALL, DE}, year={1991}, pages={313–316} }
 @inproceedings{page_riviere_heidner_mcentee_thrall_1989, title={Effect of temperature on cisplatin (CDDP) and carboplatin (CBDCA) pharmacokinetic disposition in dogs}, volume={2}, booktitle={Conference Proceedings}, author={Page, R. L. and Riviere, J. E. and Heidner, G. L. and McEntee, M. C. and Thrall, D. E.}, year={1989}, pages={499–501} }